Peripheral blood stem cell mobilization, which is important as a source of hematopoietic stem cells for transplantation, is generally performed using granulocyte colony-stimulating factor (G-CSF), but is ineffective in around 15 to 20% of patients. Combination of G-CSF with<unk>  increases the percentage of persons that respond to the therapy and produce enough stem cells for transplantation. The drug is approved for patients with lymphoma and multiple myeloma. Phase 2 clinical trials started in 2021 exploring the combination of<unk>  and MGTA-145, a CXCL2 ligand.
Plerixafor
Roxadustat
Epiestriol
Eliglustat
Truenat
Coralmyn
Proxicromil
Vilanterol